Strata Critical Medical (NASDAQ:SRTA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.10), FiscalAI reports. Strata Critical Medical had a net margin of 15.71% and a negative return on equity of 2.97%. The business had revenue of $74.08 million during the quarter.
Here are the key takeaways from Strata Critical Medical’s conference call:
- Q3 results exceeded guidance, with revenue up 50.3% year over year to $74.1 million, adjusted EBITDA rising to $9.6 million, and record free cash flow of $8.6 million. Management reiterated 2026 revenue, adjusted EBITDA, and free-cash-flow guidance.
- The clinical segment grew 20.3% sequentially and more than 30% on a comparable year-over-year basis, even as industry transplant volumes declined seasonally. Management attributed the performance to market-share gains from its integrated organ recovery, perfusion, and logistics offering, with clinical growth expected to lead in 2027.
- Logistics revenue declined 6.9% sequentially and 3.5% year over year, pressured by seasonal transplant weakness and approximately 10% shorter industry trip distances, particularly following changes to lung-allocation rules. The company expects logistics revenue to be roughly flat sequentially in Q4, while clinical drives overall growth.
- Strata ended the quarter with $41.6 million in cash and short-term investments after receiving $15.3 million from its Passenger earnout, with another $27.5 million potentially due in early 2027. The company authorized a $20 million share repurchase while maintaining plans to accelerate acquisitions at targeted mid-single-digit valuation multiples.
Strata Critical Medical Stock Performance
Shares of NASDAQ SRTA traded up $0.50 during mid-day trading on Wednesday, hitting $4.94. The stock had a trading volume of 296,365 shares, compared to its average volume of 953,803. Strata Critical Medical has a 1 year low of $3.95 and a 1 year high of $6.50. The business has a 50 day moving average price of $5.03 and a two-hundred day moving average price of $5.20. The firm has a market cap of $437.40 million, a P/E ratio of -122.37 and a beta of 2.56.
Insiders Place Their Bets
In other Strata Critical Medical news, Director Reginald Love sold 5,091 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $5.75, for a total transaction of $29,273.25. Following the completion of the sale, the director owned 146,481 shares of the company’s stock, valued at $842,265.75. This represents a 3.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 15.50% of the stock is owned by insiders.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Strata Critical Medical in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Strata Critical Medical has an average rating of “Moderate Buy” and a consensus target price of $8.00.
Strata Critical Medical Company Profile
Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.
Read More
- Five stocks we like better than Strata Critical Medical
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
Receive News & Ratings for Strata Critical Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strata Critical Medical and related companies with MarketBeat.com's FREE daily email newsletter.
